AMBUJACEM vs ULTRACEMCO
Side-by-side comparison of Ambuja Cements Ltd. and UltraTech Cement Ltd.. Descriptive only — not investment advice.
Ambuja Cements Ltd.
Cement
Quality Score: 33/100
UltraTech Cement Ltd.
Cement
Quality Score: 61/100
At a glance
| Metric | AMBUJACEM | ULTRACEMCO |
|---|---|---|
| Quality Score | 33/100 | 61/100 |
| P/E (trailing) | 23.8 | 41.7 |
| Forward P/E | 29.2 | 28.0 |
| ROE | — | — |
| Profit margin | +11.1% | +9.3% |
| Debt-to-equity | 1.21 | 29.43 |
| Dividend yield | +0.46% | +1.98% |
| 1Y price return | -26.6% | +0.4% |
| From 52w high | -28.6% | -5.8% |
| Analyst rating1 = Strong Buy, 5 = Strong Sell | 1.97 | 1.45 |
Highlighted value = better on the metric (lower for P/E, D/E, drawdown, analyst rating; higher elsewhere). Descriptive only.
Snapshots
Ambuja Cements trades at Rs 430.85, just above its 50-DMA (Rs 428.58) but 28.65% below its 52-week high and down 26.6% over the trailing 12 months. Trailing PE is 23.77x within a Cement peer set spanning ACC's 13.2x to Shree Cement's 56.5x, while 5-year earnings are down 27.5% against a smaller 7.7% revenue decline. Free cash flow was positive in only 1 of the tracked years, and the mean analyst rating stands at 1.97 across 38 analysts (1-5 scale, lower = more constructive).
ULTRACEMCO trades at ₹12,105, up 0.44% over the past 12 months and 6.73% over the past 3 months, sitting 5.78% below its 52-week high and above both its 50-day and 200-day moving averages. Trailing PE of 41.67x ranks 4th of 6 in the cement sector while forward PE of 28.01x is lower, alongside 5-year revenue growth of 15.9% and earnings growth of 16.8%. Analyst consensus across 38 analysts stands at 1.45 on a 1-5 scale (lower = more constructive).
Pros
- ✓PE of 23.77x is below 4 of the 5 other tracked cement peers, with only ACC (13.2x) lower, placing the multiple in the cheaper half of the sector range.
- ✓Absolute balance-sheet leverage is low: debt-to-equity of approximately 0.01x once the percent-scaled raw metric (1.205) is adjusted.
- ✓RSI reads neutral at 48.36 with price holding just above its 50-DMA (Rs 428.58) rather than showing an oversold extreme.
- ✓Mean analyst rating of 1.97 across 38 analysts (1-5 scale, lower = more constructive) sits toward the constructive end of the tracked coverage universe.
- ✓Quality score of 43 ranks 1st of 6 among tracked cement peers (Grasim 25, Shree Cement 39, Dalmia Bharat 30, ACC 21, Ambuja Cements 19).
- ✓Free cash flow was positive in 4 of the last 5 years tracked, with debt-to-equity at a low approximately 0.29x.
- ✓5-year revenue growth of 15.9% and earnings growth of 16.8%, alongside a forward PE of 28.01x below the trailing 41.67x.
- ✓Analyst consensus of 1.45 across 38 analysts (1-5 scale, lower = more constructive), among the more constructive readings in the dataset.
Cons
- ✗Free cash flow was positive in only 1 of the tracked years, indicating a persistent gap between cash generation and capital needs despite low balance-sheet leverage.
- ✗5-year earnings are down 27.5% against a smaller 7.7% revenue decline, and ROE has not exceeded 15% in any tracked year (consistency score of 0).
- ✗Quality score of 19 ranks last (6th of 6) among tracked cement peers (ACC 21, GRASIM 25, DALBHARAT 30, SHREECEM 39, ULTRACEMCO 43).
- ✗Stock is down 26.6% over the trailing 12 months and 28.65% below its 52-week high, trading below its 200-DMA (Rs 481.84).
- ✗Return on equity has not exceeded 15% in any of the years tracked (roeYearsAbove15 = 0), despite the top quality-score ranking among peers.
- ✗Debt-to-equity trend is recorded as rising, even though the absolute level (approximately 0.29x) remains low.
- ✗12-month price change is close to flat at +0.44%, despite the stock trading above both moving averages and near its 52-week high.
- ✗Sector-peer comparison is data-limited: 12-month price change is unavailable for all five peers and ROE for four of five, and no resistance levels were identified for the stock itself.
Want the full analysis for either stock?
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Comparison reflects current public data; consult a registered adviser before any investment decision.